Nr-axSpA, short for non-radiographic axial spondyloarthritis, is a chronic inflammatory condition that primarily affects the spine and sacroiliac joints (where your lower spine connects to your pelvis). It causes the same type of deep, persistent back pain as ankylosing spondylitis, but the key distinction is that nr-axSpA does not yet show visible structural damage on standard X-rays. The inflammation is real and measurable on MRI, but it hasn’t progressed to the bone changes that define its more advanced counterpart.
This isn’t a “pre-disease” or a mild version of something worse. Nr-axSpA is a recognized condition in its own right, and people who have it report symptom burdens that are comparable to, and sometimes higher than, those with radiographic disease.
How It Differs From Ankylosing Spondylitis
Axial spondyloarthritis exists on a spectrum. At one end is nr-axSpA, where inflammation is present but hasn’t caused permanent structural changes visible on X-ray. At the other end is radiographic axial spondyloarthritis, traditionally called ankylosing spondylitis (AS), where X-rays show clear erosion, sclerosis, or fusion of the sacroiliac joints.
The two conditions share the same underlying disease process, but they differ in some important ways beyond imaging. Nr-axSpA affects men and women almost equally (about 48.5% male in one large study of 544 patients), while ankylosing spondylitis is significantly more common in men (71% male). People with nr-axSpA also tend to have lower levels of C-reactive protein, a blood marker of inflammation, averaging 11.5 mg/l compared to 17.6 mg/l in AS. Despite this, patients with nr-axSpA actually reported slightly higher symptom scores on a standard disease activity questionnaire, scoring 4.8 out of 10 compared to 4.3 for AS. The disease burden feels the same, even if it looks different on imaging.
Nr-axSpA also shows higher rates of certain related conditions. About 39% of nr-axSpA patients experience enthesitis (painful inflammation where tendons attach to bone, particularly at the heel), compared to 33.5% of AS patients. Psoriasis (9.9% vs. 5.7%) and inflammatory bowel disease (4.2% vs. 1.7%) are also more common in the nr-axSpA group.
What the Pain Feels Like
The hallmark of nr-axSpA is inflammatory back pain, which behaves very differently from the mechanical back pain most people experience. It typically begins before age 45, comes on gradually rather than after an injury, and tends to be worst in the early morning or after periods of inactivity. Many people describe significant stiffness lasting 30 minutes or more after waking.
The counterintuitive feature is that this pain improves with movement and exercise, not with rest. Sitting still or lying down for long stretches makes it worse. If your back pain eases once you get up and start moving, that pattern is one of the most important clues pointing toward inflammatory rather than mechanical back pain. A good response to anti-inflammatory medications is another characteristic feature.
Beyond the spine, nr-axSpA can cause pain and swelling in peripheral joints, eye inflammation (uveitis), and the enthesitis and skin or gut involvement mentioned above. It’s a systemic inflammatory condition, not simply a back problem.
How It’s Diagnosed
Diagnosing nr-axSpA can be challenging precisely because X-rays look normal. The widely used classification criteria from the Assessment of Spondyloarthritis International Society (ASAS) require that a patient be under 45 with back pain lasting at least three months, then meet one of two pathways.
The first pathway is an imaging pathway: MRI shows active inflammation in the sacroiliac joints (specifically, bone marrow edema in areas right next to the joint surface), plus at least one additional feature of spondyloarthritis. The MRI findings need to appear on at least two consecutive image slices to count, though multiple lesions can qualify from a single slice. Structural changes alone, like fat deposits or erosions without active inflammation, are not sufficient.
The second pathway is clinical: a positive HLA-B27 blood test plus at least two features of spondyloarthritis. Those features include inflammatory back pain, joint swelling, uveitis, psoriasis, dactylitis (swollen “sausage” fingers or toes), Crohn’s disease or ulcerative colitis, a good response to anti-inflammatory drugs, a family history of spondyloarthritis, or elevated CRP levels.
HLA-B27, a genetic marker, is found in roughly 74 to 89% of patients with axial spondyloarthritis overall. In the nr-axSpA group specifically, the positivity rate is somewhat lower (around 55%) than in AS (69%), meaning a negative test doesn’t rule the condition out.
Does It Always Progress to Ankylosing Spondylitis?
One of the most common concerns after an nr-axSpA diagnosis is whether the condition will inevitably advance to full ankylosing spondylitis with visible bone damage. The short answer: most people do not progress. Data from the French DESIR cohort found that the net progression rate from nr-axSpA to radiographic disease was only 5.1% over five years. A four-year clinical trial similarly found that just 2 out of 44 nr-axSpA patients (4.5%) developed X-ray changes meeting the threshold for ankylosing spondylitis.
This means that for the large majority, nr-axSpA remains non-radiographic over years of follow-up. Certain factors appear to be associated with a lower likelihood of structural progression, including female sex, lower inflammatory markers, and the presence of enthesitis, psoriasis, or inflammatory bowel disease. This clinical profile, more common in nr-axSpA, may represent a phenotype that is simply less prone to the bone damage seen in AS.
Treatment Options
First-line treatment for nr-axSpA is anti-inflammatory medication, which many patients find effective at reducing pain and stiffness. When standard anti-inflammatories aren’t enough and disease activity remains high, international guidelines recommend stepping up to biologic therapies. Three main classes are used for nr-axSpA.
- TNF inhibitors block a key inflammatory protein called tumor necrosis factor. These were the first biologics approved for axial spondyloarthritis and have a strong evidence base.
- IL-17 inhibitors target a different inflammatory pathway. Several are now approved for nr-axSpA specifically, including secukinumab (Cosentyx), ixekizumab (Taltz), and bimekizumab (Bimzelx).
- JAK inhibitors are oral medications that work inside cells to dampen multiple inflammatory signals at once.
Guidelines recommend considering these advanced therapies when disease activity scores remain at 4 or above on the standard 0-to-10 scale despite adequate trials of anti-inflammatory drugs. The threshold is the same whether someone has nr-axSpA or ankylosing spondylitis. Having the non-radiographic form does not mean you’re expected to simply tolerate your symptoms.
The Role of Exercise
Exercise is considered a cornerstone of managing axial spondyloarthritis, with benefits that work independently of medication. Regular physical activity helps maintain spinal mobility, reduces stiffness, and can improve pain and fatigue over time. Supervised exercise with a physiotherapist has been shown to be more effective than home exercise alone, likely because a structured program ensures the right movements are done consistently and with proper form.
Smoking cessation is also specifically highlighted in management guidelines. Smoking is associated with worse outcomes and faster disease progression in axial spondyloarthritis, making it one of the few modifiable risk factors patients can directly control.